Johnathan Lewis, MD
Family Medicine · Camden, ARNPI 1699741298
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by GSK at 25.1% of the total. 2025 is the largest year on record at $238, 6.1 times the $39 reported in 2020. That places this record below the midpoint for family medicine clinicians in AR, where the typical reported total is $553.
Across 44 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$182
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$134
- AbbVie$67
- Novo Nordisk$57
- Merck$54
- Sanofi-aventis U.S. LLC$54
- plus $180 from 8 others
What the payments were for
- Food & beverage$727100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 10 | $182 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $134 |
| AbbVie | 4 | $67 |
| Novo Nordisk | 4 | $57 |
| Merck | 4 | $54 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Lilly USA, LLC | 3 | $41 |
| Exact Sciences | 2 | $35 |
| Novartis | 1 | $25 |
| Boston Scientific | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$727 in reported general payments places this provider in the 50th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 305 | $175,643 |
| FarxigaDapagliflozin Propanediol | 174 | $125,230 |
| OzempicSemaglutide | 101 | $113,822 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 121 | $88,424 |
| JardianceEmpagliflozin | 87 | $59,565 |
| MounjaroTirzepatide | 43 | $47,498 |
| EntrestoSacubitril/Valsartan | 79 | $39,151 |
| XareltoRivaroxaban | 57 | $38,286 |
| JanuviaSitagliptin Phosphate | 33 | $27,321 |
| OxycontinOxycodone Hcl | 25 | $25,241 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $23,096 |
| LinzessLinaclotide | 40 | $22,789 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $11,529 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $10,803 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 36 | $10,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $57 | $113,822101 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta | $182 | $102,245173 claims |
| Lilly USA, LLCMounjaro | $41 | $47,49843 claims |
| NovartisEntresto | $25 | $39,15179 claims |
| MerckJanuvia, Janumet | $54 | $38,85149 claims |
| Johnson & JohnsonXarelto | $15 | $38,28657 claims |
| AbbVieLinzess | $67 | $22,78940 claims |
| Sanofi-aventis U.S. LLCLantus | $54 | $3,37924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Camden
- Glenn GibbonsFort Smith$179K
- Hetal PatelParagould$147K
- David GersonSherwood$119K
- Scott MusickBentonville$102K
- Broderick EatonWynne$49K
- Craig LevoyBentonville$30K
- Allen BeachyFort Smith$21K
- Hunter CarringtonHot Springs$20K
- Harold BettonLittle Rock$18K
- Thad HardinConway$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.